Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment with trastuzumab deruxtecan (T-Dxd), which includes a topoisomerase I inhibitor payload.